Souhaitez-vous accéder aux communiqués récents ?

Austin, Dec. 12, 2025 (GLOBE NEWSWIRE) -- As per SNS Insider Research, The Large Molecule Drug Discovery Outsourcing Market size was valued at USD 2.84 billion in 2024 and is expected to reach USD...

New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce...

FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economyConstruction reflects company’s commitment to...

–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration- –Showed early and...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj®...

Dublin, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course (Feb 23rd - Feb 24th, 2026)" training has been added to ...

LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 9, 2026 deadline to file a lead plaintiff motion in the class action filed on...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT; “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare...

MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects...

Zenflow, Inc. announced today the U.S. FDA approval of the Zenflow Spring® Implant and Delivery System for the treatment of symptoms associated with BPH.

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...

For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib...

CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA),...

Investors who lost money in MoonLake after its stock plunged 90% due to allegedly misleading financial statements are urged to contact Hagens Berman.

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR MEDRXIV METTANT EN ÉVIDENCE LE BÉNÉFICE CLINIQUE DU MASITINIB CHEZ LES PATIENTS ATTEINTS DE SCLÉROSE LATÉRALE AMYOTROPHIQUE AVANT...

PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant...

The global fusion proteins market was valued at $32.4 billion in 2024 and is expected to reach $64.9 billion by the end of 2030 at a CAGR of 12.3%

Miami, FL, Dec. 11, 2025 (GLOBE NEWSWIRE) -- In an era where consumers are increasingly conscious of the origins and quality of their nutritional supplements, Well Minerals x MD Logic Health®'s new...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or...

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Delray Beach, FL, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Emerging markets, breakthrough technologies, and strategic M&A reshape competitive landscapeThe global molecular cytogenetics market is...

NeXtGen™ Biologics Secures Favorable Outcome in Inter-Partes Patent Review

Austin, Texas, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Medical Device Sterilization Market Size & Growth Analysis: According to SNS Insider, the Medical Device Sterilization Market size was valued at...

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE...

Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that...

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and...

Inspire Medical Systems, Inc. Stock Dropped 32% on Inspire V Delays; Contact BFA Law about the Pending Securities Class Action

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical...

60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials

Hope for PDCD Foundation submitted a petition to FDA urging approval of the first targeted potential treatment for PDCD.

Las Vegas, NV, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Introductory Pricing: $19.95 with 30% December DiscountPatchMD, the original pioneer in transdermal vitamin delivery with over 10 years of...

Ophirex announces regulatory and business developments as it continues to advance varespladib as the first oral rescue treatment for snakebite.

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular...

BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE...

-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising...

CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest...

Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host...

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing...

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial  KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be...

BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed...

Mabylon has initiated a Phase I clinical trial evaluating its novel tri-specific monoclonal antibody for the prophylactic treatment of peanut allergy.

Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission...

Ghent, Belgium, Dec. 11, 2025 (GLOBE NEWSWIRE) -- First implantation of two alfapump patients on the same dayContinuing strategy of working with Key Opinion Leaders at top tier centersStrong...

Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares Qfitlia, premier traitement abaissant le taux d’antithrombine pour le traitement de l’hémophilie,...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six...

MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns

SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted...